What are the differences between unfractionated heparin and Clexane (enoxaparin)?

Differences Between Heparin and Clexane (Enoxaparin)

Clexane (enoxaparin) is a low-molecular-weight heparin (LMWH) derived from unfractionated heparin (UFH) that offers more predictable anticoagulation, longer half-life, and simpler dosing compared to standard heparin, making it the preferred choice in most clinical scenarios except when rapid reversibility is needed or CABG surgery is planned within 24 hours. 1, 2

Key Structural and Pharmacological Differences

Molecular Composition

• Unfractionated Heparin (UFH): Heterogeneous mixture of polysaccharide chains with molecular weights ranging from 5,000-30,000 Daltons 3
• Enoxaparin (Clexane): Derived from UFH through benzylation followed by alkaline depolymerization, resulting in smaller fragments with mean molecular weight of 4,500-5,000 Daltons 2, 4

Mechanism of Action

• UFH: Acts primarily on both thrombin (Factor IIa) and Factor Xa through antithrombin binding; requires simultaneous binding to both antithrombin and thrombin for full effect 1
• Enoxaparin: Has a 4:1 ratio of anti-Factor Xa to anti-Factor IIa activity; the smaller molecular size means most fragments cannot bridge antithrombin to thrombin but retain excellent Factor Xa inhibition 1, 2

Clinical Advantages of Enoxaparin

Pharmacokinetics

• Bioavailability: Enoxaparin has 3-fold greater subcutaneous bioavailability (nearly 100% absorption) compared to UFH 5
• Half-life: Enoxaparin has significantly longer half-life (4-7 hours) versus UFH (30-60 minutes, dose-dependent) 1, 5
• Predictability: Reduced binding to plasma proteins and endothelial cells results in more consistent anticoagulant effects 1, 6

Dosing and Monitoring

• Enoxaparin: Weight-based subcutaneous dosing once or twice daily; no routine laboratory monitoring required 7, 8, 2
• UFH: Requires continuous IV infusion or frequent subcutaneous injections (2-3 times daily); needs aPTT monitoring every 6 hours to maintain therapeutic range 1

Safety Profile Differences

Bleeding Risk

Both agents have similar overall bleeding rates in most studies 7, 9, though context matters:

• In acute coronary syndromes with fibrinolysis, enoxaparin is reasonable as an alternative to UFH 10
• Critical caveat: Never switch between enoxaparin and UFH during treatment—this significantly increases bleeding risk 10

Thrombocytopenia

• Enoxaparin: Lower incidence of heparin-induced thrombocytopenia (HIT) due to reduced binding to platelet factor 4 1, 2
• UFH: Higher rates of both HIT and generalized thrombocytopenia (13.1% vs 10.4% in HORIZONS trial) 1

Other Adverse Effects

• Enoxaparin causes fewer local hematomas and gluteal ulcerations at injection sites 11, 12
• Lower incidence of elevated liver enzymes with enoxaparin 11

Clinical Efficacy Comparisons

Acute Coronary Syndromes

Enoxaparin demonstrates superior or equivalent efficacy to UFH in multiple settings:

• In ESSENCE and TIMI-11B trials, enoxaparin reduced death/MI/recurrent angina compared to UFH in unstable angina/NSTEMI 7, 8, 9
• For STEMI with fibrinolysis, enoxaparin is reasonable as an alternative to UFH (Class IIa recommendation) 10

Venous Thromboembolism

• Enoxaparin is at least as effective as UFH for both prophylaxis and treatment of VTE 7, 9, 13
• Once or twice daily enoxaparin is equivalent to continuous IV UFH for acute VTE treatment 13
• However, in renally impaired ICU patients, enoxaparin showed increased major bleeding risk (OR 1.84) compared to UFH 14

Special Populations and Dosing Adjustments

Renal Impairment

This is a critical decision point:

• Creatinine clearance <30 mL/min: Reduce enoxaparin to 1 mg/kg SC once daily 10
• Alternative: Consider UFH instead in patients with known severe renal impairment, as it doesn't require renal clearance 10
• ICU patients with renal impairment: UFH may be safer given increased bleeding risk with enoxaparin 14

Age-Related Dosing

• <75 years: Enoxaparin 30 mg IV bolus followed by 1 mg/kg SC every 12 hours 10
• ≥75 years: 0.75 mg/kg SC every 12 hours without initial IV bolus 10

Pregnancy

Neither agent crosses the placenta 5

When to Choose UFH Over Enoxaparin

Select UFH in these specific scenarios:

1. Planned CABG within 24 hours: Enoxaparin's longer half-life increases surgical bleeding risk 8
2. Need for rapid reversibility: UFH can be reversed with protamine sulfate more effectively than enoxaparin 3
3. Severe renal impairment (CrCl <30 mL/min): Particularly in ICU patients where bleeding risk is elevated 10, 14
4. During PCI: Some catheterization laboratories prefer UFH for procedural anticoagulation, though enoxaparin is acceptable 10, 8
5. Active major bleeding requiring immediate reversal: Protamine provides better reversal of UFH 3

Practical Implementation

Cost and Quality of Life

• Enoxaparin allows outpatient treatment of VTE, reducing hospitalization costs 11, 15
• Improved patient compliance due to less frequent dosing and no monitoring requirements 12
• Shorter hospital stays and reduced immobilization improve psychological outcomes 12

Common Pitfalls to Avoid

1. Never switch between agents mid-treatment—this is a Class III recommendation due to increased bleeding 10
2. Don't use enoxaparin if fondaparinux was started—increased catheter thrombosis risk 10
3. Adjust for renal function—failure to reduce dose in renal impairment significantly increases bleeding 10
4. Check platelet counts—monitor for thrombocytopenia with both agents, though less common with enoxaparin 1